Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") has recently received a letter from its sponsor institution, Dongxing Securities Co., Ltd. (hereinafter referred to as "Dongxing Securities"), regarding the change of continuous supervision sponsor representatives. Dongxing Securities is currently fulfilling its continuous supervision responsibilities for the Company's 2021 initial public offering and listing on the Growth Enterprise Market, as well as the 2023 issuance of convertible corporate bonds to unspecified objects. Dongxing Securities has appointed Mr. Zhu Haizhou and Mr. Bi Wenguo as the Company's sponsor representatives responsible for the continu
301015SZSE
Announcement on the Change of Continuous Supervision Sponsor Representatives
✨ AI Summary
Qingdao Baiyang Pharmaceutical Co., Ltd. has announced a change in its continuous supervision sponsor representatives. Dongxing Securities appointed Mr. Zhu Haizhou and Mr. Bi Wenguo as the new representatives, following the departure of Mr. Yao Wei. The continuous supervision period will last until the completion of the fundraising usage as per regulatory requirements. The board expressed gratitude to Mr. Yao Wei for his contributions during his tenure.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.